HCW Biologics Valuation
| HCWB Stock | USD 1.04 0.05 5.05% |
Today, the entity appears to be undervalued. HCW Biologics retains a regular Real Value of $9.52 per share. The prevalent price of the entity is $1.04. Our model calculates the value of HCW Biologics from analyzing the entity fundamentals such as return on asset of -0.3, and Current Valuation of 9.15 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting HCW Biologics' valuation include:
Price Book 2.7998 | Enterprise Value | Enterprise Value Ebitda (3.63) | Price Sales 7.6939 | Enterprise Value Revenue 21.6914 |
Undervalued
Today
Please note that HCW Biologics' price fluctuation is moderately volatile at this time. Calculation of the real value of HCW Biologics is based on 3 months time horizon. Increasing HCW Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since HCW Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HCW Stock. However, HCW Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.04 | Real 9.52 | Target 35.0 | Hype 0.8 | Naive 0.7 |
The real value of HCW Stock, also known as its intrinsic value, is the underlying worth of HCW Biologics Company, which is reflected in its stock price. It is based on HCW Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of HCW Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of HCW Biologics helps investors to forecast how HCW stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HCW Biologics more accurately as focusing exclusively on HCW Biologics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use HCW Biologics' intrinsic value based on its ongoing forecasts of HCW Biologics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against HCW Biologics' closest peers. If more than one evaluation category is relevant for HCW Biologics we suggest using both methods to arrive at a better estimate.
HCW Biologics Cash |
|
HCW Biologics Total Value Analysis
HCW Biologics is currently anticipated to have valuation of 9.15 M with market capitalization of 5.36 M, debt of 13.69 M, and cash on hands of 32.41 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the HCW Biologics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.15 M | 5.36 M | 13.69 M | 32.41 M |
HCW Biologics Investor Information
About 27.0% of the company shares are held by company insiders. The company recorded a loss per share of 16.41. HCW Biologics had not issued any dividends in recent years. The entity had 1:40 split on the 11th of April 2025. Based on the key indicators related to HCW Biologics' liquidity, profitability, solvency, and operating efficiency, HCW Biologics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.HCW Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. HCW Biologics has an asset utilization ratio of 8.49 percent. This suggests that the Company is making $0.0849 for each dollar of assets. An increasing asset utilization means that HCW Biologics is more efficient with each dollar of assets it utilizes for everyday operations.HCW Biologics Profitability Analysis
Based on HCW Biologics' profitability indicators, HCW Biologics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess HCW Biologics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -1.9 M | Current Value -4.6 M | Quarterly Volatility 3.3 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.35 | 0.43 |
|
|
For HCW Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HCW Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HCW Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HCW Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HCW Biologics over time as well as its relative position and ranking within its peers.
HCW Biologics Earnings per Share Projection vs Actual
By analyzing HCW Biologics' earnings estimates, investors can diagnose different trends across HCW Biologics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for HCW Biologics is based on EPS before non-recurring items and includes expenses related to employee stock options.HCW Biologics Ownership Allocation
HCW Biologics secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.HCW Biologics Profitability Analysis
The company reported the previous year's revenue of 2.57 M. Net Loss for the year was (30.02 M) with profit before overhead, payroll, taxes, and interest of 166.57 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates HCW Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in HCW Biologics and how it compares across the competition.
About HCW Biologics Valuation
The stock valuation mechanism determines HCW Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of HCW Biologics. We calculate exposure to HCW Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of HCW Biologics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 863.5 K | 965.4 K | |
| Pretax Profit Margin | (13.45) | (12.78) | |
| Operating Profit Margin | (13.21) | (13.87) | |
| Net Loss | (13.45) | (12.78) | |
| Gross Profit Margin | 0.43 | 0.35 |
HCW Biologics Current Valuation Indicators
Valuation refers to the process of determining the present value of HCW Biologics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value HCW we look at many different elements of the entity such as HCW's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as HCW Biologics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use HCW Biologics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes HCW Biologics' worth.Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |